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Summary was demonstrated that more than 50% of vein thrombi undergo
complete resolution 3 to 6 months after diagnosis (3-5).
A number of studies evaluating deep venous thrombosis (DVT) Regression of D V T depends on a balance between haemostatic and
have demonstrated that plasma levels of thrombotic and fibrinolytic fibrinolytic factors, Measurement of D-Dimer (DD), a specific fibrin
parameters change during treatment, but the relationship between degradation product, has proven to be useful for the diagnostic
thrombus regression and evolution of these markers remains unknown, management o f D V T (6-8). A number of studies have demonstrated
The objective of the present study was to correlate levels of D-Dim er that plasma levels of DD and other markers decrease during heparin
(DD) with thrombus regression as assessed by duplex scanning. therapy, but the relationship between thrombus regression and evolu-
From 44 patients treated for acute DVT, DD were determined at tion of the markers remains unknown (9-11).
diagnosis and at the end of initial heparin therapy of at least 5 days. A plasma marker that has predictive value for the outcome of a DVT
Thrombus regression was measured by repeated duplex scanning at is valuable for the long-term management of DVT, The objective of this
diagnosis and after 1 and 3 months.
DD significantly decreased during heparin treatment as compared 
with values at presentation. DD levels were significantly higher in 
the group of patients without normalization of the DVT after 3 months 
(p = 0.003). A ninefold excess tendency was seen for DD levels Methods 
> 1200 ng/ml at the end of initial treatment to be associated with poor Patients
resolution of the DVT [odds ratio 9.0, 0.95 confidence interval (Cl)
2.3-35.4]. When the patients with an established malignancy were 
excluded, the differences were even more significant (p = 0.0004 for 
DD levels after initial treatment and an odds ratio of 17.5, 0,95 C l
3.3-92.5).
These results suggest that increased DD levels after the initial phase 
of treatment are related to poor resolution of DVT after 3 months. 
These findings contribute to further insight into the process of thrombus 
regression, Furthermore high DD levels might help to identify the 
patients with a poor prognosis and could be useful to judge the efficacy 
of anticoagulant treatment.
introduction
Deep venous thrombosis (DVT) is a common disease with consider­
able morbidity. Patients with acute DVT are usually treated with an 
initial course of heparin (5 to 10 days) followed by at least 3 months of 
oral anticoagulant therapy (1,2). The extent of thrombus regression at 
the time of withdrawing anticoagulant therapy is usually not known.
The past few years duplex scanning (DS) has become a reliable 
technique to diagnose DVT. Because of its non-invasive nature, the 
technique is also useful for follow-up of DVT. A  few studies have 
prospectively assessed the outcome of acute DVT by means of DS. It
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study was to establish the relation between DD levels in the acute 
phase of D V T and the resolution of DVT after 3 months as assessed by 
serial DS.
Forty-four patients (24 men and 20 women) with a mean age of 53 years 
(range 28-82) with a first acute DVT confirmed by DS were enrolled in a 
prospective study after informed consent was obtained. All patients received 
continuous intravenous heparin infusion according to a standard protocol for at 
least five days. Heparin level was monitored by the assessment of heparin level 
with a chromogenic assay (target level 0.4-0.8 IU/ml) (12). Oral coumarin 
derivatives were started within 24 h and continued for a period of at least
3 months at doses adjusted to target an international normalized ratio (INR) 
between 2.0 and 4.0. All patients had been instructed to wear graduated 
compression stockings for the whole period.
Vascular Testing
The patients underwent repeated DS at the time of diagnosis and after 1 
and 3 months. Patients were placed in the reverse Trendelenburg position to 
examine the iliac, common femoral and superficial femoral vein. Popliteal, 
posterior tibial and remaining distal veins were studied with the leg in a 
dependent position. Images of all veins were obtained with transverse and 
longitudinal views. The technique of DS and the criteria for interpretation have 
been previously described (13).
To measure thrombus mass the technique proposed by Prandoni et al. was 
used (4); maximum compressibility of the vein was assessed, in the transverse 
section, by pressing on the vein with the transducer probe. A freeze frame 
image was obtained and the residual vein diameter was measured on line, 
expressed in millimeters. This finding was interpreted as an indicator of 
thrombus mass. Regarding the DVT outcome, worsening was reported if the 
clot extended to vein segments previously unaffected or if increased thrombus 
mass was detected. No change indicated the presence of an unaltered clot. 
Improvement was reported if a decreased thrombus mass was measured. Veins 
were considered to be normalized if they were fully compressible. According 
to the results of DS obtained at 3 months patients were divided in 2 groups: 
(1) normalized, which, indicates complete resolution and (2) not normalized, 
which means incomplete resolution of the DVT.
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Table 1 Patients’ characteristics
Normalization n=23 No normalization n—21
60 (31 ‘82)
1 2 / 9  
0 / 2 1
6.7 ± 1.7
17.7 ± 1 3 .8  
3 (14%)
0.59 ±  0.10 
278583 ±  150979 
4767 ± 4186  
1990 ±  1439
Labomtoiy Testing
At the time of diagnosis and at the end of initial therapy from all patients 
4.5 ml of blood was drawn into a vacutainer tube containing 0.5 ml CTAD 
solution (Becton Dickinson). Platelet poor plasma was prepared within one 
hour of sampling by centrifugation at 4000 X g for 10 min at 5° C. The super­
natant plasma was snap-frozen in aliquots and stored at-70° C until assayed, 
DD-concentrations were measured with an ELISA method (Fibrinostica FbDP, 
Organon Teknika). The laboratory technician and the vascular technician were 
blind for each other's results, All assays were performed with one single batch 
of the ELISA test kit.
Analysis
A Receiver Operating Curve (ROC) for DD levels at the end of heparin 
therapy was constructed by plotting the sensitivity (true positive fraction) 
towards 1-specificity (false positive fraction). For within subject comparison 
of the blood tests at the end of heparin therapy compared to baseline a paired 
t-test was used. The Wilcoxon-Mann-Whitney test was used to compare the 
blood tests depending on the resolution of DVT, A p-value of 0.05 or less was 
considered significant. The posterior probability of poor resolution in relation 
to different DD levels is presented as the odds ratio with 95% confidence inter­
vals (0.95 Cl).
Results
After 3 months 23 out of 44 patients (52%) showed complete 
resolution on DS. Table 1 shows the characteristics of the 2 groups of
false positive fraction (%)
Fig, 1 ROC curve analysis of D-Dimer levels (ng/ml) at the end of heparin 
therapy associated with poor resolution of DVT
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patients: the number of days of heparin treatment, the mean heparin 
level and the mean dose o f heparin used were not different. There was 
a small difference in time until an adequate heparin level was achieved 
and the mean age of the patients was higher in the group that did not 
normalize. All patients with distal DVT normalized within 3 months.
For the whole group of patients DD decreased significantly during 
heparin treatment (p = 0.0001). There was no significant relation 
between the location of initial thrombus and DD levels.
The ROC curve for DD levels at the end of heparin therapy is shown 
in Fig. 1. A cut-off value of 1200 ng/ml was chosen based on optimal 
sensitivity and minimal false positive fraction.
Figure 2 shows the comparison of DD levels before and after 
heparin treatment between the group of patients that normalized after 
three months and the group that did not normalize. DD levels at the end 
of initial therapy were significantly higher in the group of patients that 
did not normalize (p = 0.003). However, there was a large overlap of 
individual values between the groups. Mean values of the markers at 
the end of initial therapy remained elevated. While the patients with 
distal DVT (n = 5) were excluded DD levels at the end of heparin 
treatment were still significant (p = 0,006).
Figure 3 shows the DD levels of the same group of patients when the 
patients with an established malignancy (n = 8) are excluded. It shows 
that the differences in DD levels between the group that normalized 
and the group that did not normalize were even more significant 
(p = 0.0004).
Table 2 shows the odds ratios of different DD levels to be associated 
with poor resolution of DVT for the whole group of patients and for the 
patients without malignancy. A ninefold excess tendency was seen for 
DD levels > 1200 ng/ml after initial therapy to be associated with poor 
resolution of the DVT (odds ratio 9.0,0.95 Cl 2.3-35.4). The odds ratio 
for levels >1200 ng/ml after initial therapy for the group of patients 
without malignancy was 17.5,0.95 Cl 3.3-92.5,
Discussion
The objective of this study was to assess the time course of DD, a 
specific fibrinolytic parameter, in patients presenting an acute DVT 
treated with standard anticoagulant treatment. The second objective 
was to investigate the predictive value of this parameter for regression 
of DVT, because incomplete regression might lead to long-term 
complications like recurrent DVT or the post-thrombotic syndrome.
The recent development of assays for activation markers of the 
haemostatic and fibrinolytic system allows rapid and specific determi­
nation of these parameters in plasma. We used DD as a specific fibrin 
degradation product being increasingly used as a screening test for 
diagnosis of DVT because DD is elevated in the presence of active 
thrombosis. A high sensitivity and negative predictive value of DD 
assays has been reported in large series of patients (6-8).
In agreement with Mirshahi et al, (11) and Arcelus et al. (14) we 
found a trend but no significant correlation of DD levels with the 
location of the DVT. An explanation for this might be the influence of 
the age of the trombus and the fact that the relation between fibrin mass 
and fibrin-split products also depends on the activity of the fibrinolytic 
system, which varies among patients. Also extra vascular fibrin 
deposition may contribute to elevated DD. Because of these con- 
founders DD levels are probably of no value for the prediction of 
thrombus size in individual patients.
Previous reports indicate that, at initiation of heparin therapy, a 
sharp decrease in DD levels occurs within 1-3 days, followed by a 
continuous and slow decline towards the normal range (9-11). There
age 46 (28-75)
male / female 12 / 11
distal / proximal DVT 5 / 18
mean days heparin therapy 6.7 ±  1.7
hours until optimal heparin level 13.1 ±  9
malignancy (%) 5 (22%)
average heparin level (lU/ml) 0.59 ± 0.12
average dose of heparin (U) 284237 ±  101787
DD before treatment (ng/ml) 3763 ±  4314
DD after heparin (ng/ml) 1382 ±  1818
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Fig, 2 Evolution of plasma DD 
levels during initial heparin therapy 
in patients with and without normal­
ization after 3 months. Mean values 
± SD are also indicated
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Fig. 3 Evolution of plasma DD 
levels in the group of patients 
without malignancy during initial 
heparin therapy in patients with and 
without normalization after three 
months. Mean values ± SD are also 
indicated
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are anecdotal reports on patients with thromboembolic recurrence and 
secondary increase of DD levels (9). In the current study DD also 
decreased significantly during the initial phase of treatment. Remarka­
bly in only 4 patients DD was completely normalized (<500 ng/ml) 
at the end of initial heparin therapy. An explanation could be that 
fibrinolysis is a long lasting phenomenon which occurs independently 
of thrombin generation and of heparin therapy. Another possibility 
could be linked to the relatively long DD half-life (8 h).
We decided to evaluate outcome of DVT after 3 months because that 
is currently the recommended time to withdraw anticoagulant treatment 
after a first period of DVT (15). There are two other studies comparing 
levels of plasma markers to clinical outcome, The first study compares 
DD levels with venography after 10 days (10), During this period a 
relation was found between decrease of DD and regression o f DVT. 
Arcelus et al. evaluated plasminogen activator inhibitor (PAI) and DD 
levels with trombus regression during 6 months (14), They found a 
significant relation between PAI levels and a trend between DD levels 
and outcome of DVT, Our results demonstrate a significant relation 
between DD levels after initial therapy and regression of DVT, even 
though patients with distal DVT were excluded. Also a ninefold excess 
tendency was seen for DD levels >1200 ng/ml to be associated with 
poor resolution of the DVT (odds ratio 9.0,0.95 Cl 2.3-35.4).
Figure 3 shows that the differences between the group that normal­
ized and the group that did not normalize were even more significant 
when patients with an established malignancy (n = 8) were excluded.
Table 2 Odds ratios of DD for poor resolution of DVT at different cut-off
4
levels
cut-off level (ng/ml) Odds ratio (all patients) Odds ratio (exclusion of 
patients with malignancy)
500 3.0 3.4
700 4.6 5.0
900 5.5 10.0
1000 6.6 13.0
1200 9.0 17.5
1500 7.7 26.7
2000 3.3 6.9
3000 1.8 2.0
4000 1.1 1.1
801
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For this group of patients the odds ratio for DD levels >1200 ng/ml 
associated with poor resolution was 17,5 (0,95 Cl 3.3-92.5), This is 
not surprising concerning the fact that different types of malignancy 
also cause elevated DD levels (16-18); it was demonstrated that the 
accuracy of DD in diagnosis of DVT is also less in patients with a 
malignancy (19).
In conclusion, this study provides evidence that increased DD levels 
during the initial heparin treatment, might be related to outcome of 
DVT after 3 months, especially in patients without malignancy. To 
estimate the predictive value of an elevated DD validation in a separate 
group of patients is needed, These findings may contribute to further 
insight into the process of thrombus regression. Also it could help to 
identify the patients with a poor prognosis and may be useful to judge 
the efficacy of anticoagulant treatment. Whether or not serial measure­
ment o f DD is useful for monitoring and predicting regression of DVT, 
at what time interval this should be performed and what should be 
the best cut-off value are questions for future studies in larger patient 
populations.
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